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Background: Airway hyperresponsiveness (AHR) to indirect agents like mannitol is thought to
be dependent on concurrent airway inflammation as these stimuli exert their effects via the
release of bronchoconstricting mediators from inflammatory cells. Airway inflammation corre-
lates negatively with deep inhalation bronchoprotection against direct stimuli like methacho-
line. We hypothesised that deep inhalation bronchoprotection to methacholine would be
absent and airway inflammation would be present in individuals with AHR to inhaled mannitol.
Methods: Twenty asthmatic, otherwise healthy individuals, either gender, aged 18e65 years,
with a Visit 1 (screening) methacholine two-minute tidal breathing PC20 of 16 mg/mL or less
completed the study. Visits 2 and 3 consisted of either mannitol or deep inhalation methacho-
line challenge in random order, at least 24 h apart. All visits were completed within a period of
two weeks.
Results: Eleven of the twenty participants had AHR to mannitol (PD15  635 mg, the “re-
sponders”) and nine did not (the “non-responders”). Responders did not bronchoprotect to
methacholine via deep inhalation (doubling dose shift Z 0.7; p Z 0.13) and had high levels
of exhaled nitric oxide (geometric mean 49 ppb; range 16e109 ppb). Conversely, significant
deep inhalation bronchoprotection to methacholine occurred in the non-responder grouphosphate; AHR, airway hyperresponsiveness; ATS, American Thoracic Society; DI, deep inhalation;
eNO, fractional exhaled nitric oxide; FEV1, expiratory volume during the first second of forced
nhaled agent causing a 20% decrease in FEV1; PD15, dose of an inhaled agent causing a 15% decrease in
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860 B.E. Davis et al.(doubling dose shiftZ 1.6; pZ 0.013). This group also had significantly lower levels of exhaled
nitric oxide (geometric mean 23 ppb (range 16e45 ppb; p Z 0.015).
Conclusions: Deep inhalation bronchoprotection to methacholine and low levels of exhaled ni-
tric oxide coincide with mannitol non-responsiveness in an asthmatic population.
Clinical Trials Registration #NCT01642745 (clinicaltrials.gov).
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Bronchoprovocation testing is widely used both clinically as
a diagnostic test for asthma and investigationally in asthma
research. Agents used for this purpose have been divided
into direct acting and indirect acting [1e3]. The former
include methacholine and histamine whereas the latter
include adenosine monophosphate (AMP), exercise, cold air
and, more recently, mannitol. Direct acting agents provoke
bronchoconstriction by binding receptors on airway smooth
muscle cells. Indirect agents provoke bronchoconstriction
by causing the release of mediators such as leukotriene C4,
prostaglandin D2 and histamine from inflammatory cells,
including mast cells and/or eosinophils.
Evidence has shown that bronchoprotection to meth-
acholine, which accompanies deep inhalation in mild or
non-asthmatics is impaired in people with airway inflam-
mation [4]. Airway inflammation is believed to be required
for people to respond to indirect challenges such as
mannitol, as shown by the decrease in sensitivity to
mannitol in response to treatment with inhaled cortico-
steroids [5]. We looked at deep inspiration bronchopro-
tection to methacholine and compared it to airway
responsiveness to inhaled mannitol. We hypothesised that
deep inhalation bronchoprotection to methacholine would
be absent and airway inflammation would be present in
individuals with AHR to inhaled mannitol.
Methods
Study design
The study required three visits to the lab. All participants
completed standard tidal breathing methacholine challenge
testing at Visit 1. Participantswere then assigned to undergo a
modified (deep inhalation) tidal breathing methacholine
challenge or a mannitol dry powder inhalation challenge at
visits 2 and 3 in random order. Fractional exhaled nitric oxide
measurementswereobtainedatVisit 1 prior to spirometry and
bronchoprovocation procedures. Sputum was collected once
at visit 2 or at visit 3 following mannitol challenge. Sputum
induction with hypertonic saline was performed if a sample
wasnotproduced followingmannitol challenge.All threevisits
were conducted at the same time of day within a two-week
period. Testing on three consecutive days was allowed.
Participants
Recruitment targeted individuals with a current clinical
diagnosis of asthma who were between 18 and 65 years ofage with no significant medical co-morbidity. Participants
were required to have a positive (16 mg/mL) two min-
ute tidal breathing methacholine challenge and a base-
line FEV1 of 70% predicted at Visit 1 to be included in
the study. Previous research participants known to the
lab and individuals from the general university student
population and unknown to the lab were also considered.
Individuals with current respiratory infection or evidence
of respiratory infection within 4 weeks of Visit 1 were not
included. Asthma controller medications (e.g. long acting
beta agonists, inhaled corticosteroids and leukotriene
receptor antagonists) were not allowed during the study
or within 4 weeks of study entry. Two participants
were currently using or had recently used inhaled corti-
costeroid and were required to undergo the specified
washout period. Salbutamol use was allowed as rescue
therapy but withheld for 8 h prior to testing. Pregnant or
lactating females were excluded. Current smokers or ex-
smokers with a 10-pack year or greater history were
also excluded. Twenty-six individuals were screened. Six
had negative two minute tidal breathing methacholine
bronchoprovocation test results at screening Visit 1 and
were excluded. Twenty individuals completed the study
(Table 1). The University of Saskatchewan Biomedical
Research Ethics Board approved the study on ethical
grounds (Bio #10-196) and all participants provided
signed consent prior to undergoing any study related
procedures
Methacholine challenge
Two minute standardized tidal breathing methacholine
challenges were conducted as previously described [6]. In
brief, subjects performed baseline full flow volume spiro-
grams according to ATS Guidelines [7]. Aerosol inhalations,
which were performed at five-minute intervals from the
start of one to the start of the next, began with normal
saline (diluent) followed by doubling concentrations of
methacholine (0.03 mg/mLe16 mg/mL). Starting concen-
trations within an individual were determined from histor-
ical information or per guidelines [8]. Inhalations were
administered via facemask and with nose clips in place and
lasted for two minutes during which the participant per-
formed tidal breathing. Truncated FEV1 only maneouvers
(i.e. forceful exhalation was stopped after capturing the
FEV1) were performed at 30 and 90 s after each inhalation
until a fall in FEV1 of 17% was achieved (lowest post
diluent to lowest post methacholine). Algebraic interpola-
tion [9] or extrapolation [10] was used to calculate the
provocation concentration of methacholine causing a 20%
FEV1 fall (PC20).
Table 1 Participant characteristics.
Subject Gender Age
(years)
Height
(in)
Weight
(lbs)
Reported
or known
atopy
ICS (within
1 year)
ICS (required
4wk washout)
EIB Visit 1
FEV1 (L)
Visit 1%
predicted
FEV1
Visit 2
FEV1 (L)
Visit 3
FEV1 (L)
001 F 26 66 130 Yes No No No 2.73 78 2.78 2.74
002 F 22 66 148 Yes No No Yes 3.32 91 3.34 3.32
003 F 23 66 150 Yes Yes No No 3.33 93 3.69 3.62
004 F 28 64 186 Yes Yes No No 2.45 75 2.48 2.48
005 M 65 66 145 Yes No No No 2.39 76 2.44 2.37
006 M 35 70 180 Yes No No No 3.62 85 3.45 3.48
007 F 21 66 138 Yes Yes Yes Yes 3.81 105 3.59 3.83
008 M 24 72 220 Yes Yes No Yes 3.89 81 3.70 3.66
009 M 22 76 175 Yes No No No 5.07 96 5.00 5.16
010 F 20 63 155 No No No Yes 3.26 98 3.28 3.44
011 F 20 67 140 Yes Yes No Yes 3.61 100 3.64 3.58
012 F 25 66 205 No No No Yes 3.25 92 3.22 3.18
013 F 28 64 130 Yes No No Yes 3.27 100 3.33 3.23
014 F 25 66 166 No Yes No No 3.48 99 3.53 3.56
015 F 20 68 170 Yes No No Yes 3.05 80 3.16 3.17
016 M 46 71 246 Yes Yes No Yes 3.62 87 3.44 3.56
017 M 26 75 190 Yes No No No 5.07 100 5.02 5.29
018 M 27 73 193 Yes No No Yes 4.73 96 4.78 4.77
019 F 18 62 120 Yes No No Yes 3.03 96 3.10 3.05
020 F 35 62 117 Yes Yes Yes Yes 2.84 97 2.53 2.54
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The modified deep inhalation methacholine challenge was
conducted in the same manner as the two minute stan-
dardized tidal breathing methacholine challenge except
that 5 deep inhalations with a 5 s breath hold at total lung
capacity were incorporated every 20 s over the course of
the two minute inhalations [11]. Methacholine concentra-
tions ranged from 0.03 mg/mL to 256 mg/mL). Deep inha-
lation bronchoprotection was expressed as the doubling
dose change versus the two minute tidal breathing meth-
acholine PC20 [doubling dose shift Z log (deep inhalation
PC20  two minute tidal breathing PC20)/0.3] [12].Dry powder mannitol challenge
The dry powder mannitol challenge was performed as
previously described [13]. In brief, a capsule (0, 5, 10, 20 or
40 mg; total cumulative dose 0e635 mg) was inserted into
the Osmohaler device and punctured. The inhaler was
tilted downward and a visual check was performed to
ensure the capsule was in the holding chamber prior to
handing the device to the participant. With nose clips in
place the contents of the capsule was inhaled by rapid deep
inhalation, followed by a 5 s breath hold. Fifty-five seconds
later two truncated FEV1 maneouvers were performed. The
test was stopped when the highest post inhalation FEV1
value was 15% lower than the highest FEV1 obtained after
the 0 mg capsule or when the fall in FEV1 from one dose to
the next was 10%. In responders, results were expressed
as the cumulative dose of mannitol causing a 15% fall in
FEV1 (PD15). Results were recorded as >635 mg in non-
responders.Measurement of fractional exhaled nitric oxide
(FeNO)
FeNO was measured at screening Visit 1 prior to any other
testing procedures using a NIOX Mino (Aerocrine AB, Swe-
den) per manufacturer and ATS/ERS recommendations [14].
Participants inhaled from the machine to total lung ca-
pacity via the single use manufacturer filter/mouthpiece.
This was followed immediately by a ten second exhalation
at a flow rate of 50 ml/s against a pressure of 5 cm H2O.
Noseclips were not worn. A minimum of three measure-
ments were taken, two of which were required to be
reproducible within 10%. The mean of reproducible mea-
surements was used for comparison and analysis.
Sputum collection and processing
Sputum collection and processing was performed as previ-
ously described [15]. In brief, an attempt to collect sputum
from all participants followed mannitol challenge. If a
sample could not be produced, induction was attempted by
inhalation of 3%, 4% and 5% hypertonic saline. Samples were
kept cold and processed within two hours of collection. Cell
counts were performed by hemocytometer and recorded as
number of cells per milliliter of sputum. Aliquots of the cell
suspension underwent cytospin preparation and differential
cell counts were performed on Diff-Quik stained glass
slides.
Data analysis
The population was dichotomized into mannitol responders
(PD15  635 mg; n Z 11) and mannitol non-responders
Table 2 Results.
Subject Tidal
breathing
MCh PC20
(mg/mL)
Deep
inhalation
MCh PC20
(mg/mL)
Mannitol
PD15 (mg)
Sputum
EOS (%)
Exhaled
nitric
oxide
(ppb)
001 1.4 2.3 >635 1.7 24
002 0.96 7.1 346 1.9 32
003 1.6 1.9 580 1.0 99
004 0.23 0.21 124 n/a 50
005 0.84 1.7 >635 2.7 32
006 0.31 0.61 177 n/a 23
007 8.1 11.1 >635 1.5 17
008 0.9 0.68 587 n/a 109
009 4.4 6.6 >635 n/a 45
010 6.3 69.0 489 4.2 16
011 1.7 1.8 240 2.9 73
012 7.2 64.0 >635 1.5 16
013 1.3 2.3 523 13.6 17
014 1.9 3.7 >635 13.6 17
015 1.0 2.0 142 6.1 79
016 1.0 1.5 75 5.8 58
017 5.9 12.9 >635 n/a 39
018 8.6 256 >635 n/a 21
019 5.5 13.1 >635 n/a 17
020 0.88 0.27 145 n/a 101
MCh Z methacholine; n/a Z not available (no sample or sam-
ple not sufficient for processing).
Figure 1 a) Geometric mean tidal breathing (solid circles)
and tidal breathing plus five deep inhalations (open triangles)
methacholine PC20 values in mannitol responders (left) and
non-responders (right). b) Geometric mean fractional exhaled
nitric oxide levels in mannitol responders and non-responders.
862 B.E. Davis et al.(PD15 > 635 mg; nZ 9). Methacholine PC20 and FeNO values
were all log transformed in order to normalise the data.
Between (responder versus non-responder) and within
(responder versus responder and non-responder versus non-
responder) group comparisons were performed on meth-
acholine PC20, and FeNO data using a two-sample t-test
categorical model. We use Statistix 9.0 (Analytical Soft-
ware, Tallahassee, Florida) and a p value of less than 0.05
was considered significant.Results
Individual data are presented in Table 2. Between groups
analyses indicated mannitol responders were significantly
more sensitive to methacholine than mannitol non-
responders for both the standard two minute tidal breath-
ing methacholine challenge (geometric mean methacholine
PC20 1.0 mg/mL versus 3.8 mg/mL; p Z 0.0032) and the
modified deep inhalation methacholine challenge (geo-
metric mean methacholine PC20 1.7 mg/mL versus 11.3 mg/
mL; p Z 0.016; (Fig. 1(a)). Responders also had higher
levels of fractional exhaled nitric oxide [geometric mean
49 ppb (range 16e109 ppb) versus 23 ppb (range
16e45 ppb); p Z 0.015 Fig. 1(b)].
Within group analyses showed non-significant deep
inhalation bronchoprotection against methacholine in the
responders (geometric mean tidal breathing methacholine
PC20 1.0 mg/mL versus modified deep inhalation meth-
acholine challenge PC20 1.7 mg/mL; doubling dose
shift Z 0.7; p Z 0.13) and significant deep inhalation
bronchoprotection in the non-responders (geometric meantidal breathing methacholine PC20 3.8 mg/mL versus
modified deep inhalation methacholine challenge PC20
11.3 mg/mL; doubling dose shift Z 1.6; p Z 0.013). The
difference in dose shift between the two groups was not
significant (p Z 0.20).
Discussion
We examined whether or not individuals with AHR to
mannitol would have evidence of airway inflammation and
lack deep inhalation bronchoprotection. Fifty-five percent
of our cohort with clinically diagnosed asthma and AHR to
methacholine responded to mannitol inhalation challenge.
We also observed high levels of FeNO and no significant
deep inhalation bronchoprotection to methacholine in this
group. Conversely, the remaining forty-five percent of our
cohort did not exhibit AHR to mannitol, had lower levels of
FeNO and bronchoprotected to methacholine with deep
inhalation.
We looked at this for two reasons. First, we have pre-
viously shown that increases in FeNO and sputum eosino-
philia are associated with a loss of deep inhalation
bronchoprotection to methacholine. [4] Second, indirect
stimuli exert their effects by causing the release of bron-
choconstricting mediators from inflammatory cells [16].
A number of studies have used various approaches and
different patient populations to study the role of airway
inflammation and mannitol responsiveness. Brannan et al.
studied 18 asthmatics and noted a decrease in AHR to
mannitol following 6e9 weeks treatment with inhaled
budesonide (800e2400 mg/day) [5]. Prior to study drug,
individual treatments ranged from none to triple therapy
with inhaled corticosteroid plus short acting beta2 agonist
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mannitol challenge prior to treatment and all, with one
possible exception, had a clinically significant improvement
in mannitol responsiveness after treatment, some into the
non-responsive range (i.e. >635 mg). Leuppi et al. [17]
looked at AHR to mannitol and histamine in fifty well-
controlled asthmatics currently being treated with
inhaled steroid (mean treatment duration 6.7 years; mean
dose 1284 mg/day). Overall, forty-eight percent of partici-
pants responded to mannitol (range 205 mg-503 mg) and
thirty-percent of participants responded to histamine. No
relationship was found between mannitol or histamine
responsiveness and indices of airway inflammation,
including sputum eosinophils and FeNO.
Others have stratified the response to mannitol (PD10) by
severity and looked for an association with mild, moderate
and severe levels of AHR to methacholine and low, medium
and high levels of FeNO [18]. In this study of ICS treated
(mean ICS doses of 345 mg/day BDP equivalent) persistent
asthmatics it was shown that those with high FeNO
(>50 ppb) had severe AHR to mannitol (0e75 mg) and
methacholine (PC20 0e0.5 mg/mL) and those with low FeNO
had mild AHR to methacholine (PC20 2e8 mg/mL) and
mannitol (PD10 315e635 mg). Those with moderate AHR
(mannitol 75e315 mg and methacholine 0.5e2) also had
medium levels of FeNO (25e50 ppb). A significant differ-
ence was seen between mild and severe groups. Porsbjerg
et al. [19] looked at sputum cells counts in steroid naı¨ve
asthmatics and found that mannitol responsiveness differed
depending on inflammatory cell subtype. The greatest
response to mannitol was found in those with purely eosi-
nophilc asthma and the least in those with neutrophilic
asthma. The same was true for levels of FeNO. That is,
purely eosinophilic asthma had the highest level of FeNO.
Our study is similar to another study by Porsbjerg et al. [20]
which measured FeNO, sputum eosinophils, methacholine
responsiveness and mannitol responsiveness in steroid
naı¨ve asthmatics. While they found both stimuli to be
correlated with airway inflammation, the correlation was
stronger for mannitol with respect to both FeNO and
sputum eosinophil counts.
One factor that makes direct comparison of our current
investigation and those of Lueppi et al. [17], Anderson and
Lipworth [18] and Porsbjerg et al. [20] difficult is the dif-
ference between methacholine (or histamine) inhalation
methodology. We use tidal breathing and these in-
vestigators use deep inhalation. As has been shown by
ourselves [21] and others [22], the latter may exclude some
mild asthmatics. This may be an important consideration as
mannitol use increases and data comparisons between re-
searchers are made. The implication, and difference be-
tween our investigation and previous investigations is that
our population may have less severe AHR to direct acting
stimuli than has been previously studied. Nonetheless, we
did observe an association between AHR to mannitol, high
levels of FeNO and AHR to methacholine. We also observed
less AHR to methacholine and lower levels of FeNO in
mannitol non-responders.
Using deep inhalation bronchoprotection to methacho-
line as a means of investigating the relationship between
mannitol responsiveness and airway inflammation has not,
to our knowledge, been reported. We have previouslyshown a negative correlation between deep inhalation
bronchoprotection to methacholine and increases in FeNO
and sputum eosinophils [4]. It follows that the absence of
deep inhalation bronchoprotection may be characteristic of
the mannitol responsive airway. Our current study supports
this rationale in that the shift in AHR to methacholine with
deep inhalation was neither statistically nor clinically sig-
nificant in those who responded to mannitol challenge.
There was however an apparent trend toward broncho-
protection with deep inhalation in the mannitol responsive
group suggesting a larger sample size may influence the
result. Based on our experience with methacholine a sam-
ple of ten subjects would be appropriately powered (>99%)
to detect a clinically significant shift in PC20 of one doubling
concentration.
A limitation of our study is the absence of sputum in-
flammatory cell counts. We designed the study to include
sputum analysis. Our experience with hypertonic saline
induction of sputum is about fifty percent in individuals
with mild asthma. We anticipated improved sample reten-
tion following mannitol challenge [23] and managed to
obtain sputum from 60% of our participants. Of the twelve
that produced a sample, five had sputum eosinophilia
greater than three percent and three of the five responded
to mannitol. Seven of twelve participants responded to
mannitol if we lowered the cutoff for eosinophilia to one
percent. We were unable to draw any meaningful conclu-
sions from these data.
We provide additional evidence of a relationship be-
tween airway inflammation and AHR to mannitol in clini-
cally diagnosed asthmatics with documented (tidal
breathing) AHR to methacholine. The use of deep inhalation
bronchoprotection methodology in mild asthmatics and
other populations known to exhibit bronchoprotection with
deep inhalation may be a useful indicator of mannitol
responsiveness when objective measurement is not
possible.
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